A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.
about
Topical tacrolimus for atopic dermatitisInterventions for vitiligoInterventions for vitiligoInterventions for vitiligoHighlights in pathogenesis of vitiligoConcise review of recent studies in vitiligoVitiligo in adults and children.Treatment of localized vitiligo with targeted broadband UVB phototherapy: a pilot study.Current state of vitiligo therapy--evidence-based analysis of the literature.Vitiligo.Use of Topical Corticosteroids in Dermatology: An Evidence-based Approach.Vitiligo--Part 2--classification, histopathology and treatmentCurrent Management of Pediatric Vitiligo.Efficacy of topical calcineurin inhibitors in vitiligo.Calcineurin inhibitors and rapamycin: cancer protection or promotion?Current and emerging therapy for the management of vitiligo.A protocol for systematic reviews of Ayurveda treatmentsVitiligo: an evidence-based update. Report of the 13th Evidence Based Update Meeting, 23 May 2013, Loughborough, U.K.Polypodium leucotomos as an Adjunct Treatment of Pigmentary Disorders.Effect of 0.1% tacrolimus ointment in localized vitiligo: an open uncontrolled trialVitiligo in adults and children: surgical interventions.Double-blind, placebo-controlled, randomized study comparing 0.0003% calcitriol with 0.1% tacrolimus ointments for the treatment of endemic pityriasis alba.The expanding role of topical tacrolimus in dermatology.Pharmacologic Treatment of Vitiligo in Children and Adolescents: A Systematic Review.What's new in hypochromy.Vitiligo treatment options: an evolving scenario.Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature reviewAssigning new roles to topical tacrolimus.Tacrolimus: approved and unapproved dermatologic indications/uses-physician's sequential literature survey: part II.Prevalence of thyroid function test abnormalities and thyroid autoantibodies in children with vitiligo.Effectiveness and safety of topical tacrolimus in treatment of vitiligo.Vitiligo: a review of the published work.Evidence-based, non-surgical treatments for vitiligo: a review.Which outcomes should we measure in vitiligo? Results of a systematic review and a survey among patients and clinicians on outcomes in vitiligo trials.The pathogenesis of vitiligo.Advances in the treatment options for vitiligo: activated low-dose cytokines-based therapy.Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.Digital image analysis vs. clinical assessment to evaluate repigmentation after punch grafting in vitiligo.Potential emerging treatment in vitiligo using Er:YAG in combination with 5FU and clobetasol.Comparison of the efficacy of 308-nm excimer lamp monotherapy with topical tacrolimus or clobetasol 17-propionate combination therapies in localized vitiligo.
P2860
Q24186624-27DF8A5B-061A-4E56-A8E1-A68F5DF6C1CDQ24187979-ED5926E5-58E4-4F47-8D23-1CC598225C13Q24240527-A3A7DCF4-30BF-497C-B66D-F796BBB70AA2Q24244743-3831F8E1-7454-41DD-BFEA-12B82B39E7A3Q26851509-3A38A30D-6760-4791-B6F2-73B8693FC203Q27025963-E28BACBD-4032-48B5-9751-2DCDC5D2048DQ31004500-B549C6E8-D5E1-4410-8D87-45718732E52BQ33244383-ABD463A3-CAD6-44E4-AAE4-6471FBBCE9FBQ33286182-7CAE7072-B12E-4091-85D6-222338B65B1AQ33446628-28293FCF-FD70-4D7D-8257-B8F0AA138B5FQ33737957-9CF1A37A-08AB-4124-B61F-5EF977E6DAB7Q34140523-DA977077-1312-48FB-8270-A09A7F00EF65Q34478386-6DFAF7D7-73B9-41F1-84BC-4727A3BBD469Q34553952-4D6D3011-8B5B-4508-BE56-016778D6BA26Q34578721-8F2054F8-A2E4-4C72-93BD-25F833DD31CDQ34620297-67C1876A-4594-4D6D-90D9-BE2EAFB5FE11Q34687757-0D9B96AA-2F55-47CD-8CA9-E2C86E35CC18Q35019101-B36B6341-41C3-41CC-AFBF-D53930B1E5B7Q35136538-4A184CCE-E041-4D54-AAAD-4BA3AFF98F43Q35229052-83450A2A-1FB4-4E58-BB55-239FCE8D53EFQ35584658-FC1B9EF7-5EE0-4F67-827A-BE933346EBD6Q35942462-8CC5BC72-18F2-4D4E-B366-24352C164D8AQ36051504-8A08E662-2194-4AB6-975E-3EAD9EF5BB8CQ36202183-FAC38E65-A048-4548-BB73-59196772F4CFQ36502877-5B45A23E-CB47-4121-BE0B-B74A508344A9Q36621061-25D618AF-C643-45C8-BE8A-6E807C217909Q36885086-4051C1AB-9AF0-42BA-8FAC-60852A2C73C1Q36904866-B280FD14-1588-410A-893A-04CD88064898Q37104570-17F457D8-F6EA-4400-8221-FACCD439DED0Q37413965-885EA5B6-DCA2-4A02-BF74-ECDA5897AAFDQ37620951-8C8D2AAC-44E3-4C5D-BCAF-9C05737DE484Q37888578-A108AD6D-C027-4A7A-949B-130EBD7D3739Q37994233-0CBEEE44-DB76-40C7-BD92-10DE13339A67Q38010463-DC4B4B67-647D-4B9E-9E13-185FF818E26EQ38106804-553499C8-6B07-4A07-BDD3-879C9A976C3DQ38587330-052335A7-A86F-45AF-9E2B-D0510D55C1FEQ39723783-C98AF2ED-1006-4ECF-8929-BB51B7BBF6CBQ40036838-E9BB8E66-A450-4535-85DF-601C6AE4D7C0Q40117163-93EAC087-02A9-457F-B938-A7BBCDFDFBAFQ40399602-595ACFD4-4704-44E1-8932-8A78E0A1B90A
P2860
A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
A double-blind randomized tria ...... eatment of childhood vitiligo.
@en
A double-blind randomized tria ...... eatment of childhood vitiligo.
@nl
type
label
A double-blind randomized tria ...... eatment of childhood vitiligo.
@en
A double-blind randomized tria ...... eatment of childhood vitiligo.
@nl
prefLabel
A double-blind randomized tria ...... eatment of childhood vitiligo.
@en
A double-blind randomized tria ...... eatment of childhood vitiligo.
@nl
P2093
P1433
P1476
A double-blind randomized tria ...... eatment of childhood vitiligo.
@en
P2093
Antonio B Torres-Rubalcava
Benjamin Moncada
Carlos A Ortiz
Juan Pablo Castanedo-Cazares
Maria Bertha Torres-Alvarez
Veronica Lepe
P304
P356
10.1001/ARCHDERM.139.5.581
P577
2003-05-01T00:00:00Z